Not Disclosed (Portfolio Approach)

About Oddifact

Oddifact operates at the intersection of AI and biotech, utilizing a proprietary platform to identify new therapeutic uses for existing molecules in rare diseases, a vast and underserved market. The company's core activity involves generating high-quality, evidence-backed orphan drug designation (ODD) dossiers for regulatory submission, which it then partners with pharmaceutical companies to develop further. With a stated ambition to have 30 new drugs by 2030, Oddifact has demonstrated early traction, claiming 16 FDA ODD submissions and 11 granted designations. Its business model is primarily platform-based and pre-revenue, relying on partnerships for downstream value capture.

Therapeutic Areas